{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:39:42Z","timestamp":1792269582393,"version":"4.4.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jiac.2026.103057","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:02:14Z","timestamp":1787673734000},"page":"103057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Acute development of EBV+ T-cell lymphoproliferative disorder after treatment with rituximab for follicular lymphoma"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5405-9759","authenticated-orcid":false,"given":"Satoko","family":"Oka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuina","family":"Ueda-Akagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5915-7801","authenticated-orcid":false,"given":"Takaya","family":"Mitsuyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jiac.2026.103057_bib1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1006\/scbi.1996.0027","article-title":"EBV infection of T cells: potential role in malignant transformation","volume":"7","author":"Kelleher","year":"1996","journal-title":"Semin Cancer Biol"},{"issue":"20","key":"10.1016\/j.jiac.2026.103057_bib2","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the world health organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jiac.2026.103057_bib3","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/j.1349-7006.2007.00549.x","article-title":"Pathogenesis and mechanism of disease progression from hemophagocytic lymphohistiocytosis to Epstein-Barr virus-associated T-cell lymphoma: nuclear factor-kappa B pathway as a potential therapeutic target","volume":"98","author":"Chuang","year":"2007","journal-title":"Cancer Sci"},{"issue":"2","key":"10.1016\/j.jiac.2026.103057_bib4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/bjh.19255","article-title":"Epstein-Barr virus-associated lymphomas decoded","volume":"204","author":"Bednarska","year":"2024","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.jiac.2026.103057_bib5","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jiac.2026.103057_bib6","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.jiac.2026.103057_bib7","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1182\/blood.V71.5.1234.1234","article-title":"Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation","volume":"71","author":"Shapiro","year":"1988","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.jiac.2026.103057_bib8","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1056\/NEJM199805143382011","article-title":"Epstein-Barr virus in action in vivo","volume":"338","author":"Rickinson","year":"1998","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jiac.2026.103057_bib9","first-page":"952","article-title":"Detection of clonal Epstein-Barr virus in malignant proliferation of peripheral blood CD3+ CD8+ T cells","volume":"6","author":"Chan","year":"1992","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.jiac.2026.103057_bib10","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1172\/JCI116721","article-title":"Epstein-Barr virus-infected T lymphocytes in Epstein-Barr virus-associated hemophagocytic syndrome","volume":"92","author":"Kawaguchi","year":"1993","journal-title":"J Clin Investig"},{"key":"10.1016\/j.jiac.2026.103057_bib11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fonc.2018.00163","article-title":"Past, present, and future of rituximab-the world's first oncology monoclonal antibody therapy","volume":"8","author":"Pierpont","year":"2018","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.jiac.2026.103057_bib12","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/nri2729","article-title":"Effector and regulatory B cells: modulators of CD4+ T cell immunity","volume":"10","author":"Lund","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"10.1016\/j.jiac.2026.103057_bib13","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/10428190902934944","article-title":"The late adverse events of rituximab therapy--rare but there","volume":"50","author":"Ram","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.jiac.2026.103057_bib14","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/bjh.12293","article-title":"Advances in understanding the pathogenesis of HLH","volume":"161","author":"Usmani","year":"2013","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.jiac.2026.103057_bib15","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-012-1644-6","article-title":"Clinical analysis and prognostic significance of lymphoma-associated hemophagocytosis in peripheral T cell lymphoma","volume":"928","author":"Xie","year":"2013","journal-title":"Ann Hematol"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X26001558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X26001558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:19:04Z","timestamp":1788527944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X26001558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1341321X26001558"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2026.103057","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute development of EBV+ T-cell lymphoproliferative disorder after treatment with rituximab for follicular lymphoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2026.103057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103057"}}